Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins

Toxicon

Volumn 55, Issue 2-3, 2010, Pages 407-414

  Torii, Yasushi ^a,b   Goto, Yoshitaka ^a   Takahashi, Motohide ^c   Ishida, Setsuji ^c   Harakawa, Tetsuhiro ^a   Sakamoto, Takashi ^d   Kaji, Ryuji ^e   Kozaki, Shunji ^b   Ginnaga, Akihiro ^a  

^a Kaketsuken   (Japan)

^b Osaka Prefecture University   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d National Center Hospital of Neurology and Psychiatry   (Japan)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Botulinum toxin; CMAP; Mouse ip LD50; Neuromuscular transmission

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN C; BOTULINUM TOXIN D; BOTULINUM TOXIN E; BOTULINUM TOXIN F; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; LD 50; MOUSE; MUSCLE ACTION POTENTIAL; MUSCLE RELAXATION; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ACTION POTENTIALS; ANIMALS; BOTULINUM TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LETHAL DOSE 50; MICE; MICE, INBRED ICR; MUSCLE RELAXANTS, CENTRAL; MUSCLE, SKELETAL; NEUROMUSCULAR BLOCKING AGENTS; SYNAPTIC TRANSMISSION;

ANIMALIA; MUS; RATTUS;

EID: 72749102680     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.09.005     Document Type: Article

References (23)

1. Aoki K.R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39 12 (2001) 1815-1820
2. Bigalke H., Wohlfarth K., Irmer A., and Dengler R. Botulinum A toxin: Dysport improvement of biological availability. Exp. Neurol. 168 1 (2001) 162-170
3. Bozzi Y., Costantin L., Antonucci F., and Caleo M. Action of botulinum neurotoxins in the central nervous system: antiepileptic effects. Neurotox. Res. 9 2-3 (2006) 197-203
4. Cichon Jr. J.V., McCaffrey T.V., Litchy W.J., and Knops J.L. The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 105 2 (1995) 144-148
5. Eleopra R., Tugnoli V., Rossetto O., Montecucco C., and De Grandis D. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci. Lett. 224 2 (1997) 91-94
6. Eleopra R., Tugnoli V., Rossetto O., De Grandis D., and Montecucco C. Different time course of recovery after poisoning with botulinum neurotoxin serotypes A and E in human. Neurosci. Lett. 256 3 (1998) 135-138
7. Eleopra R., Tugnoli V., Quatrale R., Rossetto O., and Montecucco C. Different types of botulinum toxin in humans. Mov. Disord. 19 Suppl. 8 (2004) S53-S59
8. Hallis B., James B.A., and Shone C.C. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J. Clin. Microbiol. 34 8 (1996) 1934-1938
9. Jahn R., and Niemann H. Molecular mechanisms of clostridial neurotoxins. Ann. N.Y. Acad. Sci. 733 (1994) 245-255
10. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatr. 75 7 (2004) 951-957
11. Kessler K.R., and Benecke R. The EDB test - a clinical test for the detection of antibodies to botulinum toxin type A. Mov. Disord. 12 1 (1997) 95-99
12. LeClaire R.D., and Pitt M. Biological weapons defense. In: Lindler L.E., Lebeda F.J., and Korch G.W. (Eds). Biological Weapon Defense: Infectious Diseases and Counterbioterrorism (2005), Humana Press, Totowa 41-61
13. Mezaki T., Kaji R., Kohara N., Fujii H., Katayama M., Shimizu T., Kimura J., and Brin M.F. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 45 3 Pt 1 (1995) 506-508
14. Montecucco C., and Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Mirobiol. 13 1 (1994) 1-8
15. Pearce L.B., Borodic G.E., First E.R., and MacCallum R.D. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol. Appl. Pharmacol. 128 1 (1994) 69-77
16. Sakaguchi G., Ohishi I., and Kozaki S. Purification and oral toxicities of Clostridium botulinum progenitor toxins. In: Lewis G.E. (Ed). Biomedical Aspect of Botulism (1981), Academic Press, New York 21-34
17. Sakaguchi G. Clostridium botulinum toxins. Pharmacol. Ther. 19 2 (1983) 165-194
18. Schiavo G., Matteoli M., and Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80 2 (2000) 717-766
19. Sesardic D., McLellan K., Ekong T.A., and Das R.G. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacol. Toxicol. 78 5 (1996) 283-288
20. Straughan D. Progress in applying the three Rs to the potency testing of botulinum toxin type A. Altern. Lab. Anim. 34 3 (2006) 305-313
21. Takahashi M., Kameyama S., and Sakaguchi G. Assay in mice for low levels of Clostridium botulinum toxin. Int. J. Food Microbiol. 11 3-4 (1990) 271-277
22. Wictome M., Newton K., Jameson K., Hallis B., Dunnigan P., Mackay E., Clarke S., Taylor R., Gaze J., Foster K., and Shone C. Development of an in vitro bioassay for Clostridium botulinum type B neurotoxin in foods that is more sensitive than the mouse bioassay. Appl. Environ. Microbiol. 65 9 (1999) 3787-3792
23. Yoneda S., Shimazawa M., Kato M., Nonoyama A., Torii Y., Nishino H., Sugimoto N., Kozaki S., and Hara H. Comparison of the therapeutic indexes of different molecular forms of botulinum toxin type A. Eur. J. Pharmacol. 508 1-3 (2005) 223-229